The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

[1]  R. Loos,et al.  The genetics of obesity: from discovery to biology , 2021, Nature Reviews Genetics.

[2]  L. Castéra.  Screening for liver fibrosis in primary care: Focus on subjects above 40 and with metabolic risk factors. , 2021, United European gastroenterology journal.

[3]  M. Buti,et al.  A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  O. Shibolet,et al.  Ultra‐processed food is associated with features of metabolic syndrome and non‐alcoholic fatty liver disease , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[5]  J. Lazarus,et al.  A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[6]  Elin Hoffmann Dahl,et al.  Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C , 2021, Journal of viral hepatitis.

[7]  H. Tilg,et al.  Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. , 2021, The lancet. Gastroenterology & hepatology.

[8]  N. Méndez-Sánchez,et al.  Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience. , 2021, Journal of hepatology.

[9]  Roger Williams,et al.  Validation of the liver traffic light test as a predictive model for survival and development of liver‐related events , 2021, JGH open : an open access journal of gastroenterology and hepatology.

[10]  J. Lazarus,et al.  MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective , 2021, Alimentary pharmacology & therapeutics.

[11]  H. Graessner,et al.  Rare disease care pathways in the EU: from odysseys and labyrinths towards highways , 2021, Journal of Community Genetics.

[12]  M. Hochuli,et al.  Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. , 2021, Journal of hepatology.

[13]  A. Bonetti,et al.  Implications of drugs with rebate in Europe , 2021, The Lancet regional health. Europe.

[14]  E. Eriksson,et al.  Discrimination against the elderly in health‐care services: a systematic review , 2021, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[15]  C. Trautwein,et al.  Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency , 2021, Gut.

[16]  P. Easterbrook,et al.  Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis , 2021, The Lancet. Global health.

[17]  V. de Lédinghen,et al.  Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[18]  A. Gomaa,et al.  Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. , 2021, Journal of hepatology.

[19]  M. Marmot,et al.  Changing behaviour: an essential component of tackling health inequalities , 2021, BMJ.

[20]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[21]  C. Stephens,et al.  Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry. , 2021, Journal of hepatology.

[22]  B. Stuart,et al.  Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data , 2021, BMJ Open.

[23]  Ethnic and racial inequity and inequality in health and science: a call for action , 2021, EClinicalMedicine.

[24]  V. Wong,et al.  Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement , 2021, Hepatology.

[25]  S. Hamid,et al.  The changing scenario of hepatitis D. , 2021, Journal of hepatology.

[26]  M. Alghamdi,et al.  From NAFLD to MAFLD: Nurse and allied health perspective , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[27]  B. Popkin,et al.  Sugar-sweetened beverage taxes: Lessons to date and the future of taxation , 2021, PLoS medicine.

[28]  QuanQiu Wang,et al.  COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States , 2020, EClinicalMedicine.

[29]  P. Reiss,et al.  HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. , 2020, The lancet. HIV.

[30]  H. El‐Serag,et al.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.

[31]  L. Henry,et al.  Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD , 2020, Journal of internal medicine.

[32]  D. Heymann,et al.  Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage , 2020, The Lancet.

[33]  C. Lionis,et al.  Burden of metabolic syndrome among primary care patients in Crete, Greece: A descriptive study , 2020, The European journal of general practice.

[34]  T. Baumert.  The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology. , 2020, Journal of hepatology.

[35]  Mai Mehrez,et al.  The NAFLD‐MAFLD debate: Eminence vs evidence , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[36]  J. Shaw,et al.  The Lancet Commission on diabetes: using data to transform diabetes care and patient lives , 2020, The Lancet.

[37]  A. O'Neil,et al.  Ultraprocessed food and chronic noncommunicable diseases: A systematic review and meta‐analysis of 43 observational studies , 2020, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[38]  H. Goyal,et al.  NAFLD and COVID-19: a Pooled Analysis , 2020, SN Comprehensive Clinical Medicine.

[39]  V. Jaddoe,et al.  Associations Between Intake of Sugar‐Containing Beverages in Infancy With Liver Fat Accumulation at School Age , 2020, Hepatology.

[40]  D. Raben,et al.  Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[41]  M. Mialon,et al.  Food industry political practices in Chile: “the economy has always been the main concern” , 2020, Globalization and Health.

[42]  H. Nair,et al.  The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries , 2020, The Lancet Infectious Diseases.

[43]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[44]  J. Dufour,et al.  Redefining fatty liver disease: an international patient perspective. , 2020, The lancet. Gastroenterology & hepatology.

[45]  Kong Y. Chen,et al.  Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. , 2020, Cell metabolism.

[46]  J. Dumortier,et al.  Alcohol Consumption the Day of Liver Transplantation for Alcohol‐Associated Liver Disease Does Not Affect Long‐Term Survival: A Case‐Control Study , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[47]  J. Lazarus,et al.  A global investment framework for the elimination of hepatitis B , 2020, Journal of Hepatology.

[48]  V. Chandrashekhar.  The burden of stigma. , 2020, Science.

[49]  H. Tilg,et al.  Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals , 2020, Gut.

[50]  K. Khunti,et al.  Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis , 2020, EClinicalMedicine.

[51]  R. Horton.  Offline: COVID-19 is not a pandemic , 2020, The Lancet.

[52]  P. Sumithran,et al.  Delays in healthcare consultations about obesity - Barriers and implications. , 2020, Obesity research & clinical practice.

[53]  C. Mathers,et al.  NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4 , 2020, The Lancet.

[54]  L. Moreno,et al.  Consideration of Social Disadvantages for Understanding and Preventing Obesity in Children , 2020, Frontiers in Public Health.

[55]  Lorena Rodríguez Osiac,et al.  Changes in Nutrient Declaration after the Food Labeling and Advertising Law in Chile: A Longitudinal Approach , 2020 .

[56]  J. Pawlotsky,et al.  Impact of COVID-19 on global HCV elimination efforts , 2020, Journal of Hepatology.

[57]  J. Breda,et al.  A Snapshot of European Children’s Eating Habits: Results from the Fourth Round of the WHO European Childhood Obesity Surveillance Initiative (COSI) , 2020, Nutrients.

[58]  Shana Harris,et al.  Care during COVID-19: Drug use, harm reduction, and intimacy during a global pandemic , 2020, International Journal of Drug Policy.

[59]  V. de Lédinghen,et al.  French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long , 2020, BMC Infectious Diseases.

[60]  R. Pranata,et al.  Body mass index and outcome in patients with COVID-19: A dose–response meta-analysis , 2020, Diabetes & Metabolism.

[61]  M. Hellard,et al.  A model of the economic benefits of global hepatitis C elimination: an investment case. , 2020, The lancet. Gastroenterology & hepatology.

[62]  J. Lazarus,et al.  Progress towards elimination goals for viral hepatitis , 2020, Nature Reviews Gastroenterology & Hepatology.

[63]  H. Innes,et al.  Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival. , 2020, Public health.

[64]  R. Arena,et al.  The global food syndemic: The impact of food insecurity, Malnutrition and obesity on the healthspan amid the COVID-19 pandemic , 2020, Progress in Cardiovascular Diseases.

[65]  E. Ghigo,et al.  Changes in Weight and Nutritional Habits in Adults with Obesity during the “Lockdown” Period Caused by the COVID-19 Virus Emergency , 2020, Nutrients.

[66]  S. Bagcchi.  Stigma during the COVID-19 pandemic , 2020, The Lancet Infectious Diseases.

[67]  G. MacGregor,et al.  Obesity and covid-19: the role of the food industry , 2020, BMJ.

[68]  S. Bhatt,et al.  Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe , 2020, Nature.

[69]  P. Donnan,et al.  Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. , 2020, The lancet. Gastroenterology & hepatology.

[70]  N. G. Davies,et al.  Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study , 2020, The Lancet Public Health.

[71]  F. Antoñanzas,et al.  Overcoming fragmentation of health research in Europe: lessons from COVID-19 , 2020, The Lancet.

[72]  A. Craxì,et al.  Will the COVID-19 pandemic affect HCV disease burden? , 2020, Digestive and Liver Disease.

[73]  H. Tilg,et al.  From NAFLD to MAFLD: when pathophysiology succeeds , 2020, Nature Reviews Gastroenterology & Hepatology.

[74]  P. Read,et al.  Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  Tony Kirby,et al.  Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities , 2020, The Lancet Respiratory Medicine.

[76]  K. Pottie,et al.  Strengthening screening for infectious diseases and vaccination among migrants in Europe: What is needed to close the implementation gaps? , 2020, Travel medicine and infectious disease.

[77]  C. Stedman,et al.  Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  J. Strang,et al.  Global opioid agonist treatment: A review of clinical practices by country. , 2020, Addiction.

[79]  M. Serper,et al.  Telemedicine in Liver Disease and Beyond: Can the COVID‐19 Crisis Lead to Action? , 2020, Hepatology.

[80]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[81]  Jing Xu,et al.  Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study , 2020, Journal of Hepatology.

[82]  T. Berg,et al.  Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper , 2020, JHEP Reports.

[83]  G. Alexander,et al.  An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19 , 2020, Annals of Internal Medicine.

[84]  V. Salomaa,et al.  Combined Effects of Alcohol and Metabolic Disorders in Patients With Chronic Liver Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[85]  Z. Jakab,et al.  Refugee and migrant health in the COVID-19 response , 2020, The Lancet.

[86]  Jingmin Zhao,et al.  Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology , 2020, Open forum infectious diseases.

[87]  P. Hayes,et al.  Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study , 2020, Gut.

[88]  Marie Costa,et al.  Screening and care for alcohol use disorder in France: expectations, barriers and levers using a mixed-methods approach , 2020, BMC Public Health.

[89]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[90]  M. Colombo.  EASL clinical practice guidelines for the management of occupational liver diseases , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[91]  P. Vickerman,et al.  Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England. , 2020, Addiction.

[92]  T. H. Nguyen,et al.  The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The lancet. Gastroenterology & hepatology.

[93]  P. Kamath,et al.  Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project , 2020, Hepatology.

[94]  B. Levy,et al.  Global reach of ageism on older persons’ health: A systematic review , 2020, PloS one.

[95]  A. Bianco,et al.  School-Based Intervention Programs for Preventing Obesity and Promoting Physical Activity and Fitness: A Systematic Review , 2020, International journal of environmental research and public health.

[96]  M. Hellard,et al.  A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. , 2019, The International journal on drug policy.

[97]  Josephine G. Walker,et al.  Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study , 2019, The Lancet. Global health.

[98]  M. Touvier,et al.  Ultraprocessed Food Consumption and Risk of Type 2 Diabetes Among Participants of the NutriNet-Santé Prospective Cohort. , 2019, JAMA internal medicine.

[99]  F. Tacke,et al.  New drugs for NAFLD: lessons from basic models to the clinic , 2019, Hepatology International.

[100]  F. Lammert,et al.  Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. , 2019, Journal of hepatology.

[101]  S. Gudbjörnsdottir,et al.  Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[102]  J. Rehm,et al.  Global Burden of Alcohol Use Disorders and Alcohol Liver Disease , 2019, Biomedicines.

[103]  M. Mckee,et al.  Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK , 2019, The Lancet.

[104]  J. Izopet,et al.  Hepatitis E virus infections in Europe. , 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[105]  N. Martin,et al.  Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. , 2019, Journal of theoretical biology.

[106]  S. Heymsfield,et al.  Stigma and obesity: the crux of the matter. , 2019, The Lancet. Public health.

[107]  A. Gayet-Ageron,et al.  Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals , 2019, PloS one.

[108]  C. Millett,et al.  Ultra-processed foods and excessive free sugar intake in the UK: a nationally representative cross-sectional study , 2019, BMJ Open.

[109]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[110]  M. Carrieri,et al.  Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. , 2019, The International journal on drug policy.

[111]  R. Bataller,et al.  Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[112]  P. Tien,et al.  Food Insecurity May Be an Independent Risk Factor Associated with Nonalcoholic Fatty Liver Disease among Low-Income Adults in the United States. , 2019, The Journal of nutrition.

[113]  P. Hegyi,et al.  Baveno Criteria Safely Identify Patients With Compensated Advanced Chronic Liver Disease Who Can Avoid Variceal Screening Endoscopy: A Diagnostic Test Accuracy Meta-Analysis , 2019, Front. Physiol..

[114]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[115]  J. Hodson,et al.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study , 2019, Journal of hepatology.

[116]  J. Fernández-Real,et al.  Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. , 2019, Medicina clinica.

[117]  A. Lohse,et al.  Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER , 2019, Orphanet Journal of Rare Diseases.

[118]  C. Henderson,et al.  Interventions to Reduce Ageism Against Older Adults: A Systematic Review and Meta-Analysis. , 2019, American journal of public health.

[119]  E. Barnes,et al.  Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa , 2019, BMC Public Health.

[120]  N. Thomas,et al.  Improving coding and primary care management for patients with chronic kidney disease: an observational controlled study in East London. , 2019, The British journal of general practice : the journal of the Royal College of General Practitioners.

[121]  Josephine G. Walker,et al.  The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. , 2019, The lancet. Gastroenterology & hepatology.

[122]  T. Karlsen,et al.  EASL Clinical Practice Guidelines: Drug-induced liver injury. , 2019, Journal of hepatology.

[123]  T. Ayer,et al.  Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study , 2019, BMJ Open.

[124]  K. Dobson,et al.  Workplace Antistigma Programs at the Mental Health Commission of Canada: Part 1. Processes and Projects , 2019, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[125]  D. Houghton,et al.  Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[126]  S. Zelber-Sagi.  Minding the Gap Between Clinical Trials and Treatment With the Mediterranean Dietary Pattern for Patients With Nonalcoholic Fatty Liver Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[127]  J. Holmes,et al.  Comparing alcohol taxation throughout the European Union , 2019, Addiction.

[128]  David L. Thomas.  Global Elimination of Chronic Hepatitis. , 2019, The New England journal of medicine.

[129]  J. Llovet,et al.  The oncogenic role of hepatitis delta virus in hepatocellular carcinoma , 2019, JHEP reports.

[130]  C. Franceschi,et al.  The peculiar aging of human liver: A geroscience perspective within transplant context , 2019, Ageing Research Reviews.

[131]  M. Mimiaga,et al.  Strategies used by people who inject drugs to avoid stigma in healthcare settings. , 2019, Drug and alcohol dependence.

[132]  M. Buti,et al.  Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. , 2019, Journal of hepatology.

[133]  A. Charlett,et al.  Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention , 2019, BMC Medicine.

[134]  Laurence H. Schnabel,et al.  Association Between Ultraprocessed Food Consumption and Risk of Mortality Among Middle-aged Adults in France , 2019, JAMA internal medicine.

[135]  S. Alavian,et al.  Mass migration to Europe: an opportunity for elimination of hepatitis B virus? , 2019, The lancet. Gastroenterology & hepatology.

[136]  E. Guallar,et al.  Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study , 2019, BMC Cancer.

[137]  Rachel K. Johnson,et al.  Public Policies to Reduce Sugary Drink Consumption in Children and Adolescents , 2019, Pediatrics.

[138]  T. Hallett,et al.  Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model , 2019, The Lancet.

[139]  E. Wouters,et al.  Stigma in health facilities: why it matters and how we can change it , 2019, BMC Medicine.

[140]  R. Peeling,et al.  Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. , 2019, The lancet. Gastroenterology & hepatology.

[141]  Ross A. Hammond,et al.  The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report , 2019, The Lancet.

[142]  W. Willett,et al.  Food in the Anthropocene: the EAT–Lancet Commission on healthy diets from sustainable food systems , 2019, The Lancet.

[143]  N. Martin,et al.  Cost-Effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in The United States. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[144]  R. Horton,et al.  Obesity needs to be put into a much wider context , 2019, The Lancet.

[145]  C. Sirlin,et al.  Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial , 2019, JAMA.

[146]  P. Roderick,et al.  Local care and treatment of liver disease (LOCATE) – A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care , 2018, PloS one.

[147]  A. Marshall,et al.  Supportive and palliative care in people with cirrhosis: International systematic review of the perspective of patients, family members and health professionals. , 2018, Journal of hepatology.

[148]  M. Heijmans,et al.  Evidence on the effectiveness of health literacy interventions in the EU: a systematic review , 2018, BMC Public Health.

[149]  H. D. de Melker,et al.  Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country , 2018, PloS one.

[150]  Yoosoo Chang,et al.  Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study , 2018, The American Journal of Gastroenterology.

[151]  Marie Costa,et al.  Barriers and levers in screening and care for alcohol use disorders among French general practitioners: results from a computer-assisted telephone interview-based survey , 2018, Alcoholism Treatment Quarterly.

[152]  J. Lazarus,et al.  Pathways to ensure universal and affordable access to hepatitis C treatment , 2018, BMC Medicine.

[153]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[154]  X. Qi,et al.  Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. , 2018, The lancet. Gastroenterology & hepatology.

[155]  R. Facchetti,et al.  Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. , 2018, Journal of hepatology.

[156]  B. Hanratty,et al.  GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care. , 2018, The British journal of general practice : the journal of the Royal College of General Practitioners.

[157]  R. Puhl,et al.  Weight‐based victimization from friends and family: implications for how adolescents cope with weight stigma , 2018, Pediatric obesity.

[158]  G. Dubnov-Raz,et al.  Preferred weight‐related terminology by parents of children with obesity , 2018, Acta paediatrica.

[159]  J. Lazarus,et al.  Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. , 2018, Journal of hepatology.

[160]  R. Loomba,et al.  Systematic review with meta‐analysis: risk of hepatocellular carcinoma in non‐alcoholic steatohepatitis without cirrhosis compared to other liver diseases , 2018, Alimentary pharmacology & therapeutics.

[161]  A. Tomiyama,et al.  How and why weight stigma drives the obesity ‘epidemic’ and harms health , 2018, BMC Medicine.

[162]  H. Hong,et al.  Association between cotinine‐verified smoking status and risk of nonalcoholic fatty liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[163]  M. Manns,et al.  The Lancet–EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities , 2018, The Lancet.

[164]  G. Dore,et al.  Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[165]  C. Byrne,et al.  Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults , 2018, British Medical Journal.

[166]  J. Lazarus,et al.  The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations , 2018, Seminars in Liver Disease.

[167]  H. Cortez‐Pinto,et al.  EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. , 2018, Journal of hepatology.

[168]  E. Tsochatzis,et al.  Non-alcoholic fatty liver disease and the interface between primary and secondary care. , 2018, The lancet. Gastroenterology & hepatology.

[169]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[170]  G. Pera,et al.  High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population‐Based Study , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[171]  J. Kao,et al.  Review article: the prevention of hepatitis B‐related hepatocellular carcinoma , 2018, Alimentary pharmacology & therapeutics.

[172]  P. Bower,et al.  Management of multimorbidity using a patient-centred care model: a pragmatic cluster-randomised trial of the 3D approach , 2018, The Lancet.

[173]  M. Plummer,et al.  Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide , 2018, International journal of cancer.

[174]  A. Darzi,et al.  Modelling impacts of food industry co-regulation on noncommunicable disease mortality, Portugal , 2018, Bulletin of the World Health Organization.

[175]  F. Tacke,et al.  «The times they are a'changin'» - Positioning the European Association for the Study of the Liver in the changing landscape of hepatology. , 2018, Journal of hepatology.

[176]  A. Coats,et al.  Benefits and limitations of implementing Chronic Care Model (CCM) in primary care programs: A systematic review. , 2018, International journal of cardiology.

[177]  J. Marrero,et al.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.

[178]  C. Boucher,et al.  Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[179]  Y. Hiasa,et al.  Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: A longitudinal cohort study , 2018, PloS one.

[180]  M. Thiele,et al.  Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. , 2018, Gastroenterology.

[181]  M. Jauffret-Roustide,et al.  Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. , 2018, Journal of hepatology.

[182]  V. Wong,et al.  Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta‐analysis of a complex issue , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[183]  M. Clèries,et al.  Economic burden of cirrhosis in Catalonia: a population-based analysis , 2018, BMJ Open.

[184]  N. Roberts,et al.  Nutritional labelling for healthier food or non‐alcoholic drink purchasing and consumption , 2018, The Cochrane database of systematic reviews.

[185]  M. Touvier,et al.  Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort , 2018, British Medical Journal.

[186]  S. Riordan,et al.  Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study , 2018, PloS one.

[187]  A. Wutich,et al.  Obesity stigma as a globalizing health challenge , 2018, Globalization and Health.

[188]  L. Tavoschi,et al.  Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups , 2018, BMC Infectious Diseases.

[189]  C. Quinten,et al.  Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014 , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[190]  J. Lazarus,et al.  Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. , 2018, The lancet. Gastroenterology & hepatology.

[191]  J. Verne,et al.  Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health-care use, and place of death in England. , 2018, The lancet. Gastroenterology & hepatology.

[192]  Benyamin Hoseini,et al.  Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis , 2018, SAGE open medicine.

[193]  R. Reintjes,et al.  Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries , 2018, BMC Infectious Diseases.

[194]  M. Kudo.  Management of Hepatocellular Carcinoma in Japan as a World-Leading Model , 2017, Liver Cancer.

[195]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[196]  E. Godfrey,et al.  Guidelines on the management of abnormal liver blood tests , 2017, Gut.

[197]  T. Hallett,et al.  Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries , 2017, BMC Infectious Diseases.

[198]  H. Hagan,et al.  Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta‐analysis , 2017, Addiction.

[199]  J. Leung,et al.  Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.

[200]  J. Lazarus,et al.  Micro-elimination - A path to global elimination of hepatitis C. , 2017, Journal of hepatology.

[201]  K. Kharbanda,et al.  Treatment options for alcoholic and non-alcoholic fatty liver disease: A review , 2017, World journal of gastroenterology.

[202]  L. Ye,et al.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus , 2017, Medicine.

[203]  S. Noworolski,et al.  Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. , 2017, Gastroenterology.

[204]  J. Desenclos,et al.  Continuum of hepatitis C care in France: A 20-year cohort study , 2017, PloS one.

[205]  P. Angeli,et al.  Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections , 2017, The American Journal of Gastroenterology.

[206]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[207]  B. Hanratty,et al.  How can primary care enhance end-of-life care for liver disease? Qualitative study of general practitioners’ perceptions and experiences , 2017, BMJ Open.

[208]  Tangchun Wu,et al.  Independent and joint effects of moderate alcohol consumption and smoking on the risks of non-alcoholic fatty liver disease in elderly Chinese men , 2017, PloS one.

[209]  J. Pirenne,et al.  Adult Liver Allocation in Eurotransplant , 2017, Transplantation.

[210]  John P H Wilding,et al.  Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation , 2017, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[211]  K. Khunti,et al.  Type 2 diabetes , 2017, The Lancet.

[212]  T. Card,et al.  Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study , 2017, BMJ Open.

[213]  P. Newsome,et al.  The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016 , 2017, Digestive Diseases.

[214]  M. Manns,et al.  EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. , 2017, Journal of hepatology.

[215]  J. Scannell,et al.  Evidence for the effectiveness of minimum pricing of alcohol: a systematic review and assessment using the Bradford Hill criteria for causality , 2017, BMJ Open.

[216]  F. Greaves,et al.  A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective , 2017, The Lancet.

[217]  Ioan Sporea,et al.  EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version) , 2017, Ultraschall in der Medizin - European Journal of Ultrasound.

[218]  T. Card,et al.  Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. , 2017, The lancet. Gastroenterology & hepatology.

[219]  R. Levy,et al.  The UN Decade of Nutrition, the NOVA food classification and the trouble with ultra-processing , 2017, Public Health Nutrition.

[220]  O. Shibolet,et al.  Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients , 2017, World journal of gastroenterology.

[221]  D. Hedrich,et al.  Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[222]  Jean-Michel Pawlotsky,et al.  Hepatitis C virus infection , 2017, Nature Reviews Disease Primers.

[223]  R. Bataller,et al.  Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA , 2017, BMJ Open.

[224]  B. Swinburn,et al.  The share of ultra-processed foods and the overall nutritional quality of diets in the US: evidence from a nationally representative cross-sectional study , 2017, Population Health Metrics.

[225]  W. Yeo,et al.  Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance , 2017, British Journal of Cancer.

[226]  M. Martínez-González,et al.  Ultra‐Processed Food Consumption and the Incidence of Hypertension in a Mediterranean Cohort: The Seguimiento Universidad de Navarra Project , 2016, American journal of hypertension.

[227]  A. Barritt,et al.  NAFLD and liver transplantation: Current burden and expected challenges. , 2016, Journal of hepatology.

[228]  C. Grilo,et al.  Perceived weight discrimination and chronic medical conditions in adults with overweight and obesity , 2016, International journal of clinical practice.

[229]  Laurent Castera,et al.  Screening for liver fibrosis in the general population: a call for action. , 2016, The lancet. Gastroenterology & hepatology.

[230]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[231]  M. Laurant,et al.  Improving the delivery of brief interventions for heavy drinking in primary health care: outcome results of the Optimizing Delivery of Health Care Intervention (ODHIN) five-country cluster randomized factorial trial. , 2016, Addiction.

[232]  M. Davenport,et al.  Biliary atresia and other cholestatic childhood diseases: Advances and future challenges. , 2016, Journal of hepatology.

[233]  K. Sinha,et al.  The Effect of Introducing a Minimum Price on the Distribution of Alcohol Purchase: A Counterfactual Analysis. , 2016, Health economics.

[234]  R. Hultcrantz,et al.  Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. , 2016, Journal of hepatology.

[235]  C. Hellerbrand,et al.  Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease , 2016, Digestive Diseases.

[236]  E. Davies,et al.  Assessment and management of cirrhosis in people older than 16 years: summary of NICE guidance , 2016, British Medical Journal.

[237]  Jo Cranwell,et al.  Alcohol and Tobacco Content in UK Video Games and Their Association with Alcohol and Tobacco Use Among Young People , 2016, Cyberpsychology Behav. Soc. Netw..

[238]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[239]  E. Crook,et al.  Obesity Stigma and Bias. , 2016, The journal for nurse practitioners : JNP.

[240]  W. Jiménez,et al.  Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis , 2016, PloS one.

[241]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[242]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[243]  S. Hill,et al.  Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis , 2016, PLoS medicine.

[244]  M. Mittleman,et al.  A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[245]  N. Sheron,et al.  Effect of policy, economics, and the changing alcohol marketplace on alcohol related deaths in England and Wales , 2016, British Medical Journal.

[246]  P. Monsivais,et al.  Why Are Some Population Interventions for Diet and Obesity More Equitable and Effective Than Others? The Role of Individual Agency , 2016, PLoS medicine.

[247]  A. Gasbarrini,et al.  Years of life that could be saved from prevention of hepatocellular carcinoma , 2016, Alimentary pharmacology & therapeutics.

[248]  N. Sheron.  Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths. , 2016, Journal of hepatology.

[249]  P. Thokala,et al.  Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective , 2016, PharmacoEconomics.

[250]  J. Aronson,et al.  Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature , 2016, BMC Medicine.

[251]  B. Swinburn,et al.  A parent‐based intervention to promote healthy eating and active behaviours in pre‐school children: evaluation of the MEND 2–4 randomized controlled trial , 2016, Pediatric obesity.

[252]  S. Riedel-Heller,et al.  Obesity and discrimination – a systematic review and meta‐analysis of observational studies , 2016, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[253]  D. Mozaffarian,et al.  Ultra-processed foods and added sugars in the US diet: evidence from a nationally representative cross-sectional study , 2016, BMJ Open.

[254]  P. Watkins,et al.  Drug-induced liver injury , 2015, Nature reviews. Disease primers.

[255]  A. Aro,et al.  Policy recommendations for rare disease centres of expertise. , 2015, Evaluation and program planning.

[256]  David C. Jones,et al.  Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’ , 2015, Gut.

[257]  L. Plank,et al.  Nutrition in liver transplantation: too little or too much? , 2015, Current opinion in clinical nutrition and metabolic care.

[258]  Denise C. Park,et al.  Obesity and Aging: Consequences for Cognition, Brain Structure, and Brain Function , 2015, Psychosomatic medicine.

[259]  J. Goss,et al.  Pediatric Liver Transplant Center Volume and the Likelihood of Transplantation , 2015, Pediatrics.

[260]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[261]  W. Dietz,et al.  Management of obesity: improvement of health-care training and systems for prevention and care , 2015, The Lancet.

[262]  A. Ejaz,et al.  Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 535 Patients. , 2015, JAMA surgery.

[263]  T. Card,et al.  Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography , 2015, BMJ Open.

[264]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[265]  J. Trujols.  The brain disease model of addiction: challenging or reinforcing stigma? , 2015, The lancet. Psychiatry.

[266]  R. Puhl,et al.  Health Consequences of Weight Stigma: Implications for Obesity Prevention and Treatment , 2015, Current Obesity Reports.

[267]  Jennifer L. Harris,et al.  Energy drinks and adolescents: what's the harm? , 2015, Nutrition reviews.

[268]  M. Kudo,et al.  Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[269]  M. van Ryn,et al.  Impact of weight bias and stigma on quality of care and outcomes for patients with obesity , 2015, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[270]  Henrique Duarte,et al.  The burden of alcoholism in fifteen years of cirrhosis hospital admissions in Portugal , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[271]  C. Beckwith,et al.  Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program , 2015, Journal of General Internal Medicine.

[272]  Sue Roberts,et al.  Delivering person centred care in long term conditions , 2015, BMJ : British Medical Journal.

[273]  M. Bellis,et al.  Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis , 2014, The Lancet.

[274]  B. Druss,et al.  Mental health-related stigma in health care and mental health-care settings. , 2014, The lancet. Psychiatry.

[275]  A. Joshi,et al.  An Overview of Chronic Disease Models: A Systematic Literature Review , 2014, Global journal of health science.

[276]  M. Thursz,et al.  Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation , 2014, Alimentary pharmacology & therapeutics.

[277]  S. Patten,et al.  Opening Minds: The Mental Health Commission of Canada’s Anti-Stigma Initiative: Key Ingredients of Anti-Stigma Programs for Health Care Providers: A Data Synthesis of Evaluative Studies , 2014 .

[278]  Mohsen Naghavi,et al.  Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis , 2014, BMC Medicine.

[279]  J. Breda,et al.  WHO European Childhood Obesity Surveillance Initiative: body mass index and level of overweight among 6–9-year-old children from school year 2007/2008 to school year 2009/2010 , 2014, BMC Public Health.

[280]  A. Gasbarrini,et al.  Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. , 2014, Journal of hepatology.

[281]  J. Lazarus,et al.  Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.

[282]  I. Binswanger,et al.  Confronting Inadvertent Stigma and Pejorative Language in Addiction Scholarship: A Recognition and Response , 2014, Substance abuse.

[283]  Emmanuel A Tsochatzis,et al.  Liver cirrhosis , 2014, The Lancet.

[284]  Alan Brennan,et al.  Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study , 2014, The Lancet.

[285]  R. Puhl,et al.  Putting people first in obesity , 2014, Obesity.

[286]  S. Shenkin,et al.  Lifestyle intervention for improving school achievement in overweight or obese children and adolescents. , 2014, The Cochrane database of systematic reviews.

[287]  R. Gambino,et al.  Gender specific medicine in liver diseases: a point of view. , 2014, World journal of gastroenterology.

[288]  C. Monteiro,et al.  Food Classification Systems Based on Food Processing: Significance and Implications for Policies and Actions: A Systematic Literature Review and Assessment , 2014, Current Obesity Reports.

[289]  J. Niederdeppe,et al.  Effects of messages from a media campaign to increase public awareness of childhood obesity , 2014, Obesity.

[290]  Micah R. Lattanner,et al.  Self-regulatory processes underlying structural stigma and health. , 2014, Social science & medicine.

[291]  Valerie Purdie-Vaughns,et al.  Intervening within and across levels: a multilevel approach to stigma and public health. , 2014, Social science & medicine.

[292]  S. Hadler,et al.  The impact of hepatitis B vaccine in China and in the China GAVI Project. , 2013, Vaccine.

[293]  A. Treno,et al.  Minimum alcohol prices and outlet densities in British Columbia, Canada: estimated impacts on alcohol-attributable hospital admissions. , 2013, American journal of public health.

[294]  A. Frigo,et al.  How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. , 2013, Journal of hepatology.

[295]  P. J. Chilton,et al.  Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study. , 2013, Health technology assessment.

[296]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[297]  M. Heydtmann,et al.  Survival and re-admission of patients admitted with alcoholic liver disease to a West of Scotland hospital , 2013, Scottish medical journal.

[298]  V. Hope,et al.  Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association , 2013, Epidemiology and Infection.

[299]  Bruce G. Link,et al.  Stigma as a fundamental cause of population health inequalities. , 2013, American journal of public health.

[300]  M. Stepanova,et al.  Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C , 2013, Alimentary pharmacology & therapeutics.

[301]  C. Lewis,et al.  Perceived weight discrimination in the CARDIA study: Differences by race, sex, and weight status , 2013, Obesity.

[302]  S. Wakeman.  Language and addiction: choosing words wisely. , 2013, American journal of public health.

[303]  P. Portincasa,et al.  Management of chronic liver disease by general practitioners in southern Italy: unmet educational needs. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[304]  B. Neal,et al.  Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries , 2013, The Lancet.

[305]  M. Stellefson,et al.  The Chronic Care Model and Diabetes Management in US Primary Care Settings: A Systematic Review , 2013, Preventing chronic disease.

[306]  Chien-Jen Chen,et al.  Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. , 2013, American journal of epidemiology.

[307]  P. Hayes,et al.  Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost‐effectiveness , 2013, Hepatology.

[308]  M. Levi,et al.  Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy , 2013, Human vaccines & immunotherapeutics.

[309]  P. Roderick,et al.  Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease , 2012, Comparative hepatology.

[310]  S. Macdonald,et al.  The raising of minimum alcohol prices in Saskatchewan, Canada: impacts on consumption and implications for public health. , 2012, American journal of public health.

[311]  D. Schwarzfuchs,et al.  Four-year follow-up after two-year dietary interventions. , 2012, The New England journal of medicine.

[312]  Nicolas Rüsch,et al.  Challenging the public stigma of mental illness: a meta-analysis of outcome studies. , 2012, Psychiatric services.

[313]  D. Torres,et al.  Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[314]  W. Heuvel,et al.  Experienced discrimination amongst European old citizens , 2011 .

[315]  U. Nöthlings,et al.  Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. , 2011, Journal of the National Cancer Institute.

[316]  B. McMahon,et al.  Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch‐up immunization program , 2011, Hepatology.

[317]  M. Davenport,et al.  Biliary atresia in England and Wales: results of centralization and new benchmark. , 2011, Journal of pediatric surgery.

[318]  E. Yeoh,et al.  Unplanned readmission rates, length of hospital stay, mortality, and medical costs of ten common medical conditions: a retrospective analysis of Hong Kong hospital data , 2011, BMC health services research.

[319]  N. Sheron,et al.  Social inequalities in alcohol‐related adult mortality by National Statistics Socio‐economic Classification, England and Wales, 2001–03 , 2011, Health statistics quarterly.

[320]  A. McCullough,et al.  Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. , 2011, Journal of hepatology.

[321]  F. Durand.  The quest for equity in liver transplantation: another lesson learned from women. , 2011, Journal of hepatology.

[322]  R. Quinn,et al.  Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. , 2011, Journal of hepatology.

[323]  Y. le Cam,et al.  The added value of centres of expertise for rare disease patients in Europe , 2010, Orphanet Journal of Rare Diseases.

[324]  J. Rehm,et al.  Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. , 2010, Drug and alcohol review.

[325]  H. Tilg,et al.  Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. , 2010, Minerva gastroenterologica e dietologica.

[326]  B. Baumberg.  World trade law and a framework convention on alcohol control , 2010, Journal of Epidemiology & Community Health.

[327]  G. Marchesini,et al.  The Effect of Lifestyle Changes in Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[328]  H. Sørensen,et al.  Clinical course of alcoholic liver cirrhosis: A Danish population‐based cohort study , 2010, Hepatology.

[329]  K. Straif,et al.  Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. , 2009, International journal of epidemiology.

[330]  M. Davenport,et al.  Biliary atresia , 2009, The Lancet.

[331]  Yu Wang,et al.  Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. , 2009, Vaccine.

[332]  Chien-Jen Chen,et al.  Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. , 2009, Journal of the National Cancer Institute.

[333]  Judith Wylie-Rosett,et al.  Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. , 2009, Circulation.

[334]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years , 2009, Gut.

[335]  Laura Smart Richman,et al.  Perceived discrimination and health: a meta-analytic review. , 2009, Psychological bulletin.

[336]  N. Rüsch,et al.  Self‐stigma and the “why try” effect: impact on life goals and evidence‐based practices , 2009, World psychiatry : official journal of the World Psychiatric Association.

[337]  Kathryn Angus,et al.  Impact of alcohol advertising and media exposure on adolescent alcohol use: a systematic review of longitudinal studies. , 2009, Alcohol and alcoholism.

[338]  C. Verrill,et al.  Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases. , 2009, Addiction.

[339]  D. Foxcroft,et al.  The effect of alcohol advertising, marketing and portrayal on drinking behaviour in young people: systematic review of prospective cohort studies , 2009, BMC public health.

[340]  P. Portincasa,et al.  Improving nonalcoholic fatty liver disease management by general practitioners: a critical evaluation and impact of an educational training program. , 2008, Journal of gastrointestinal and liver diseases : JGLD.

[341]  M. Davenport,et al.  European Biliary Atresia Registries: Summary of a Symposium , 2008, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie.

[342]  H. Sørensen,et al.  Alcoholic cirrhosis in Denmark – population-based incidence, prevalence, and hospitalization rates between 1988 and 2005: A descriptive cohort study , 2008, BMC gastroenterology.

[343]  Ralph B. D'Agostino,et al.  Soft Drink Consumption and Risk of Developing Cardiometabolic Risk Factors and the Metabolic Syndrome in Middle-Aged Adults in the Community , 2007, Circulation.

[344]  E. Cholongitas,et al.  Female Liver Transplant Recipients with the Same GFR as Male Recipients Have Lower MELD Scores—A Systematic Bias , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[345]  Norman Sartorius,et al.  Stigma: ignorance, prejudice or discrimination? , 2007, British Journal of Psychiatry.

[346]  I. Guha,et al.  Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease , 2006, Gut.

[347]  J. Sarles,et al.  Management of patients with biliary atresia in France: Results of a decentralized policy 1986‐2002 , 2006, Hepatology.

[348]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[349]  A. Nemtsov.  Alcohol-related human losses in Russia in the 1980s and 1990s. , 2002, Addiction.

[350]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[351]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[352]  B. Howard,et al.  Sugar and Cardiovascular Disease A Statement for Healthcare Professionals From the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association , 2002 .

[353]  Alan D. Lopez,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. , 2002, The New England journal of medicine.

[354]  T. Karlsen,et al.  Primary sclerosing cholangitis , 2001, The Lancet.

[355]  H. Adami,et al.  Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma , 2000, International journal of cancer.

[356]  D. Kelly,et al.  The frequency and outcome of biliary atresia in the UK and Ireland , 2000, The Lancet.

[357]  E H Wagner,et al.  Chronic disease management: what will it take to improve care for chronic illness? , 1998, Effective clinical practice : ECP.

[358]  B S Blumberg,et al.  Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[359]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[360]  J. Buckels,et al.  Successful liver transplantation in babies under 1 year. , 1993, BMJ.

[361]  J. Buckels,et al.  Liver transplantation in babies and children with extrahepatic biliary atresia. , 1993, Journal of pediatric surgery.

[362]  G. Garcia‐Tsao,et al.  Screening and Surveillance of Varices in Patients With Cirrhosis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[363]  G. Marchesini,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. , 2019, Transplantation.

[364]  H. Hagan,et al.  Check Hep C: A Community-Based Approach to Hepatitis C Diagnosis and Linkage to Care in High-Risk Populations , 2018, Journal of public health management and practice : JPHMP.

[365]  T. Lobstein,et al.  The commercial use of digital media to market alcohol products: a narrative review , 2017, Addiction.

[366]  P. Hayes,et al.  Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. , 2017, Journal of hepatology.

[367]  T. Lobstein,et al.  Alcohol marketing and youth alcohol consumption: a systematic review of longitudinal studies published since 2008 , 2017, Addiction.

[368]  C. Brookes,et al.  France's Évin Law on the control of alcohol advertising: content, effectiveness and limitations , 2017, Addiction.

[369]  Mary McCarthy,et al.  Sustainable general practice: looking across Europe. , 2016, The British journal of general practice : the journal of the Royal College of General Practitioners.

[370]  J. Dufour,et al.  Hepatocellular carcinoma and lifestyles. , 2016, Journal of hepatology.

[371]  W. Hall,et al.  The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises? , 2015, The lancet. Psychiatry.

[372]  M. Blachier,et al.  Report Title: The burden of liver disease in Europe: a review of available epidemiological data , 2013 .

[373]  George Davey Smith,et al.  Supplementary Table S1 , 2008 .

[374]  P. Montupet,et al.  Determinants of life span after Kasai operation at the era of liver transplantation. , 1997, The Tohoku journal of experimental medicine.

[375]  C. Gonçalves,et al.  [Hepatocellular carcinoma]. , 1988, Arquivos de gastroenterologia.

[376]  V. Arroyo,et al.  Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.